Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy

Journal of Hepatology

Volumn 49, Issue 6, 2008, Pages 892-898

  Piroth, Lionel ^a   Carrat, Fabrice ^b   Larrat, Sylvie ^c   Goderel, Isabelle ^b   Martha, Benoit ^a   Payan, Christopher ^d   Lunel Fabiani, Françoise ^e   Bani Sadr, Firouze ^b,f   Perronne, Christian ^g   Cacoub, Patrice ^h   Pol, Stanislas ⁱ   Morand, Patrice ^c  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f HÔPITAL TENON   (France)

^g RAYMOND POINCARÉ HOSPITAL   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ NONE   (France)

Author keywords

GBV C; HCV; HIV; Occult hepatitis B; SEN V

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; LIVER ENZYME; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD EXAMINATION; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; DISEASE DURATION; DISEASE TRANSMISSION; FEMALE; FIBROSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS G VIRUS; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MIXED INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEN VIRUS; SERODIAGNOSIS; STEATOSIS; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COMORBIDITY; DNA VIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLAVIVIRIDAE INFECTIONS; GB VIRUS C; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PREVALENCE; RIBAVIRIN; TORQUE TENO VIRUS; VIRUS DISEASES;

EID: 55749100512     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.06.024     Document Type: Article

References (50)

1. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
2. Chung R., Andersen J., Volberding P., Robbins G., Liu T., Sherman K., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
3. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
4. Nunez M., Miralles C., Berdun M.A., Losada E., Aguirrebengoa K., Ocampo A., et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 23 (2007) 972-982
5. Kojima H., Kaita K.D., Zhang M., Giulivi A., and Minuk G.Y. Genomic analysis of a recently identified virus (SEN virus) and genotypes D and H by polymerase chain reaction. Antiviral Res 60 (2003) 27-33
6. Sagir A., Kirschberg O., Heintges T., Erhardt A., and Haussinger D. SEN virus infection. Rev Med Virol 14 (2004) 141-148
7. Jones J.F., Kulkarni P.S., Butera S.T., and Reeves W.C. GB virus-C - a virus without a disease: we cannot give it chronic fatigue syndrome. BMC Infect Dis 5 (2005) 78
8. Chen S., Kao C., Chen C., Shih C., Hsu M., Chao C., et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 278 (2003) 591-607
9. Wagner A., Denis F., Weinbreck P., Loustaud V., Autofage F., Rogez S., et al. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 18 (2004) 569-571
10. Neau D., Winnock M., Jouvencel A., Faure M., Castera L., Legrand E., et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 40 (2005) 750-753
11. Rodriguez-Torres M., Gonzalez-Garcia J., Brau N., Sola R., Moreno S., Rockstroh J., et al. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?. J Med Virol 79 (2007) 694-700
12. Pogany K., Zaaijer H.L., Prins J.M., Wit F.W., Lange J.M., and Beld M.G. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses 21 (2005) 922-926
13. Quarleri J., Moretti F., Bouzas M., Laufer N., Carrillo M., Giuliano S., et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-co-infected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses 23 (2007) 525-531
14. Piroth L, Lafon M, Binquet C, Bertillon P, Gervais A, Lootvoet E, et al. Occult hepatitis B in HIV-HCV co-infected patients. Scand J Infect Dis, doi:10.1080/00365540801918511.
15. Re III V.L., Frank I., Gross R., Dockter J., Linnen J.M., Giachetti C., et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 44 (2007) 315-320
16. Mphahlele M.J., Lukhwareni A., Burnett R.J., Moropeng L.M., and Ngobeni J.M. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 35 (2006) 14-20
17. Filippini P., Coppola N., Pisapia R., Scolastico C., Marrocco C., Zaccariello A., et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20 (2006) 1253-1260
18. Zignego A., Fontana R., Puliti S., Barbagli S., Monti M., Caraccia G., et al. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 142 (1997) 535-544
19. Bonino F. Effect of interferon-alpha on progression to hepatocellular carcinoma: a retrospective cohort study. Lancet 351 (1998) 1535-1539
20. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M., and Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341 (1999) 22-26
21. De Maria N., Colantoni A., Friedlander L., Leandro G., Idilman R., Harig J., et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 12 (2000) 3529-3536
22. Fukuda R., Ishimura N., Hamamoto S., Moritani M., Uchida Y., Ishihara S., et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 63 (2001) 220-227
23. Ferraro D., Bonura C., Giglio M., Di Stefano R., Almasio P., Di Marco V., et al. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. J Biol Regul Homeost Agents 17 (2003) 172-175
24. Fabris P., Brown D., Tositti G., Bozzola L., Giordani M., Bevilacqua P., et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 29 (2004) 160-166
25. Raffa G., Maimone S., Cargnel A., Santantonio T., Antonucci G., Massari M., et al. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 21 (2007) 2171-2175
26. Berzsenyi M.D., Bowden D.S., Kelly H.A., Watson K.M., Mijch A.M., Hammond R.A., et al. Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology 133 (2007) 1821-1830
27. Schwarze-Zander C., Blackard J.T., Zheng H., Addo M.M., Lin W., Robbins G.K., et al. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis 194 (2006) 410-419
28. Christensen P.B., Fisker N., Mygind L.H., Krarup H.B., Wedderkopp N., Varming K., et al. GB virus C epidemiology in Denmark: different routes of transmission in children and low- and high-risk adults. J Med Virol 70 (2003) 156-162
29. Rey D., Fraize S., Vidinic J., Meyer P., Fritsch S., Labouret N., et al. High prevalence of GB virus C/hepatitis G virus RNA in patients infected with human immunodeficiency virus. J Med Virol 57 (1999) 75-79
30. Puig-Basagoiti F., Cabana M., Guilera M., Giménez-Barcons M., Sirera G., Tural C., et al. Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV. J Acquir Immune Defic Syndr 23 (2000) 89-94
31. Lau D.T., Miller K.D., Detmer J., Kolberg J., Herpin B., Metcalf J.A., et al. Hepatitis G virus and human immunodeficiency virus coinfection: response to interferon-alpha therapy. J Infect Dis 180 (1999) 1334-1337
32. Souza I.E., Allen J.B., Xiang J., Klinzman D., Diaz R., Zhang S., et al. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia. J Clin Microbiol 44 (2006) 3105-3113
33. Tillmann H., Heiken H., Knapik-Botor A., Heringlake S., Ockenga J., Wilber J., et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 345 (2001) 715-724
34. Xiang J., Wunschmann S., Diekema D.J., Klinzman D., Patrick K.D., George S.L., et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 345 (2001) 707-714
35. Rodriguez B., Woolley I., Lederman M.M., Zdunek D., Hess G., and Valdez H. Effect of GB virus C coinfection on response to antiretroviral treatment in human immunodeficiency virus-infected patients. J Infect Dis 187 (2003) 504-507
36. Van der Bij A.K., Kloosterboer N., Prins M., Boeser-Nunnink B., Geskus R.B., Lange J.M., et al. GB virus C coinfection and HIV-1 disease progression: the Amsterdam cohort study. J Infect Dis 191 (2005) 678-685
37. Bjorkman P., Flamholc L., Molnegren V., Marshall A., Guner N., and Widell A. Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART. AIDS 21 (2007) 1641-1643
38. Sheng W.H., Hung C.C., Wu R.J., Wang J.T., Chen P.J., Chang S.C., et al. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy. Clin Infect Dis 44 (2007) 584-590
39. Bjorkman P., Flamholc L., Nauclér A., Molnegren V., Wallmark E., and Widell A. GB virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality. AIDS 18 (2004) 877-886
40. Inoue T., Sakamoto M., Akahane Y., Okamoto H., Miyakawa Y., and Mayumi M. Response to interferon of GB virus C and hepatitis C virus in patients with chronic hepatitis. Am J Gastroenterol 92 (1997) 1981-1985
41. Yu M., Chuang W., Dai C., Chen S., Lin Z., Hsieh M., et al. GB virus C/hepatitis G virus infection in chronic hepatitis patients with and without interferon-alpha therapy. Antiviral Res 52 (2001) 241-249
42. Oshita M., Hayashi N., Mita E., Iio S., Hiramatsu N., Hijioka T., et al. GBV-C/HGV infection in chronic hepatitis C patients: its effect on clinical features and interferon therapy. J Med Virol 55 (1998) 98-102
43. Tanaka T., Hess G., Schlueter V., Zdunek D., Tanaka S., and Kohara M. Correlation of interferon treatment response with GBV-C/HGV genomic RNA and anti-envelope 2 protein antibody. J Med Virol 57 (1999) 370-375
44. Williams C., Klinzma D., Yamashita T., Xiang J., Polgreen P., Rinaldo C., et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 350 (2004) 981-990
45. Umemura T., Alter H., Tanaka E., Orii K., Yeo A., Shih J., et al. SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis C. Hepatology 35 (2002) 953-959
46. Sagir A., Adams O., Antakyali M., Oette M., Erhardt A., Heintges T., et al. SEN virus has an adverse effect on the survival of HIV-positive patients. AIDS 19 (2005) 1091-1096
47. Quiros-Roldan E., Torti C., Imberti L., Casari S., Soriano V., Moretti F., et al. SENV infection in HIV-positive patients: prevalence, subtype characterization, and impact on HIV disease progression. AIDS Res Hum Retrovir 19 (2003) 1079-1082
48. Kao J., Chen W., Chen P., Lai M., and Chen D. SEN virus infection in patients with chronic hepatitis C: preferential coinfection with hepatitis C genotype 2a and no effect on response to therapy with interferon plus ribavirin. J Infect Dis 187 (2003) 307-310
49. Sagir A., Adams O., Kirschberg O., Erhardt A., Heintges T., and Haussinger D. SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration. World J Gastroenterol 10 (2004) 1893-1897
50. Rigas B., Hasan I., Rehman R., Donahue P., Wittkowski K., and Lebovics E. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet 358 (2001) 1961-1962